From: Adam Brosius[adam@pharmasales.com]

Sent: Wed 8/5/2020 8:25:00 PM (UTC)

To: Charles Boyd[CharlesB@Safechain.com]; Garrett

Mellott[garrett@pharmasales.com]; Dhruv Ralhan[dhruv@shs.healthcare];

Invoice 9229[9229sales@gmail.com]

Subject: Fwd: blank T3

Attachment: ATT00001.htm

Attachment: image001.png

Attachment: image002.png

Attachment: ATT00002.htm

Attachment: BLANK T3.pdf

Attachment: ATT00003.htm

Please see attached super simple to fill out

lets get someone on it ASAP

Need product from BLVD

Worldwide Pharma Sales Group Inc.

455 NE Fifth Avenue Suite D434

Delray Beach, Florida 33483

215.595.3932

adam@pharmasales.com

----- Forwarded message -----

From: Charles Boyd < Charles B@safechain.com >

Date: Wed, Aug 5, 2020 at 4:18 PM

Subject: Fwd: blank T3

To: Adam Brosius (Contact) < adam@pharmasales.com >

Charlie Boyd | Founder & CEO Safe Chain Solutions, LLC 822 Chesapeake Drive Cambridge, MD 21613

> GOVERNMENT EXHIBIT 128 1:24-cr-20255-WPD

office: <u>855.437.5727</u> www.SafeChain.com

Begin forwarded message:

From: Abbie Divilio <AbbieD@Safechain.com> Date: August 5, 2020 at 4:08:54 PM EDT

To: Charles Boyd < Charles B@Safechain.com>

Subject: blank T3

Please see attached for a blank T3 template

Case 1:24-cr-20255-WPD Document 231-4 Entered on FLSD Docket 11/07/2025 Page 3 of 4

Safe Chain Solutions, LLC

822 Chesapeake Drive | Cambridge, MD 21613

office: 855.437.5727 x1017 | fax: 866.930.1128

www.SafeChain.com |

Drug Supply Chain Security Act Document

(TI) Transaction Information

| Drug Name, Strength, Dosage Form, Container Size: | | | |
|---|----------|-----------------|-----------------------|
| | | | Reference Number: |
| NDC: | | | Document Type: |
| Lot Number | Quantity | Unique Serial # | Reference Date: |
| | | | |
| | | | |
| | | | |
| | | | |
| (TH) Transaction | History | | |
| Manufacturer's Na | - | | |
| Manufacturer's in | | | |
| SOLD TO: | | | SHIPPED TO: |
| Name: | | | Name: |
| Address: | | | Address: |
| Date Purchased & Ref : | | | Date Received & Ref : |
| SOLD TO: | | | SHIPPED TO: |
| Name: | | | Name: |
| Address: | | | Address: |
| Data Damal | I O D-f | | |
| Date Purchased & Ref : | | | Date Received & Ref : |
| SOLD TO: | | | SHIPPED TO: |
| Name: | | | Name: |
| Address: | | | Address: |
| Date Purchased & Ref : | | | Date Received & Ref : |
| SOLD TO: | | | SHIPPED TO: |
| Name: | | | Name: |
| Address: | | | Address: |
| Date Purchased & Ref : | | | Date Received & Ref : |
| SOLD TO: | | | SHIPPED TO: |
| Name: | | | Name: |
| Address: | | | Address: |
| Date Purchased & Ref : | | | Date Received & Ref : |

- (TS) Transaction Statement: This Company complied with each applicable subsection of FDCA Sec. 581 (27) (A) (G)
- (A) is authorized as required under the Drug Supply Chain Security Act;
- (B) received the product from a person that is authorized as required under the Drug Supply Chain Security Act;
- (C) received transaction information and a transaction statement from the prior owner of the product, as required under section 582;
- (D) did not knowingly ship a suspect or illegitimate product;
- (E) had systems and processes in place to comply with verification requirements under section 582;
- (F) did not knowingly provide false transaction information; and
- (G) did not knowingly alter the transaction history.

Page: 1 of 1 pages.